

CanHMVr

The Canadian Home Mechanical Ventilation Research Network

*Reshma Amin and
Francine Buchanan*



RFA 4 – New Trial Networks



Accelerating
Clinical Trials
Accélérer les
Essais Cliniques




CIHR
IRSC

Canadian Institutes of
Health Research
Instituts de recherche
en santé du Canada

Need for CAN HMVr

- HMV population is medically fragile, intense healthcare utilization and associated costs
- Despite intensity of needs, no previous national RCTs
- **Network Aim:** *To develop, evaluate and implement innovative treatment strategies and healthcare system delivery models to improve the health and healthcare experience of the HMV population from the perspectives of patients and families and the healthcare system*



CANHMVr-52 members from 7 provinces

Reshma Amin




- Ontario
- Co-Chair

Andrea Gershon



- Ontario
- Scientific Committee Chair

Lena Xiao




- BC
- Early Career Investigator

Colleen O'Connell



- New Brunswick
- Knowledge and Mobilization

Francine Buchanan




- Ontario
- Co-Chair

Homira Osman



- Ontario
- Knowledge Translation Chair

Indra Narang




- Ontario
- EDIIA Lead

Andrea Loewen



- Alberta
- Knowledge User

David Zielinski



- Quebec
- Capacity Building Co-Chair

Susi VanderWyk



- BC
- Patient Engagement

Tim Ramsay




- Ontario
- ACT trials unit lead

Sherri Katz




- Ontario
- Peds HMV Lead

CAN HMVr Governance



Network Engagement

- **Scientific Committee:** scientific oversight, leads internal grant review and adjudicates new protocols
- **Capacity Building Committee:** unites trial sites and shares expertise, mentorship program, CanTRAIN
- **Knowledge Translation Committee:** trains network members to help evaluate their impact
- **Patient Engagement:** patient partners and non-profit organizations embedded into network
- **EDIIA:** include underrepresented populations, understand epidemiology of indigenous population using HMV and consult with our resources with research in the indigenous population



Can HMr Progress

- Core Outcome set for HMr and James Lindt Alliance Priority setting work underway
- ACT International Trials application submitted in partnership with Australia: 3TLA Study- 12 wk RCT of in-lab PSG vs usual care to improve NIV adherence in ALS
- 12 wk RCT of in-lab PSG vs home initiation of NIV in pediatric NMD and NIV vs CPAP for COPD

IMPACT

- Evidence and patient/family informed RCTs and outcomes
- ALS is the most common NMD in adults and survival is 2 years post dx
- Improved NIV adherence improves survival
- Limited access to pediatric PSG labs, are in-home starts an option?
- Change care for COPD

Question Period

Can HMVr: The Canadian Home Mechanical Ventilation Research Network

Dr. Reshma Amin

02:00